The University of Pittsburgh has announced a research collaboration with biopharmaceutical company Shire Plc designed to advance treatments for rare diseases.
Under the agreement, Pitt’s research expertise will augment Shire’s research, development and commercial experience to target treatment of diseases that are overlooked by big pharmaceutical companies. The agreement is a relatively new one for Pitt, but the type the university has identified as a strategic priority.
“Public funding for higher education is changing,” Pitt Chancellor Patrick Gallagher said in a prepared statement on Monday. “For Pitt to continue to engage in research of impact, including research into rare diseases, we must seek out external partnerships.”
Under the agreement, Pitt and Shire will issue joint requests for proposals from university scientists for new medicines. Shire will fund selected projects, which could ultimately result in a licensing agreement.
Shire is headquartered in Ireland, with a North American headquarters in Lexington, Mass.
Kris B. Mamula:kmamula@post-gazette.com or 412.263-1699.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.